Therefore, it is evident that CD19-CAR-T cells can eliminate cancer cells by targeting “on-tumor” CD19 and concurrently result in normal B-cell aplasia (“on-target/off-tumor effect”), which can be utilized as a tool for measuring CAR-T cell persistence after desirable outcomes have been achieved [13,14,15]. This evidence concerns the gene CD19 and cancer.